Nektar Therapeutics
NKTR
142 hedge funds and large institutions have $1.29B invested in Nektar Therapeutics in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 42 reducing their positions, and 17 closing their positions.
77% more call options, than puts
Call options by funds: $17.9M | Put options by funds: $10.1M
31% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 42
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
10% more capital invested
Capital invested by funds: $1.18B → $1.29B (+$113M)
2% more funds holding
Funds holding: 139 → 142 (+3)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$287M |
| 2 |
Primecap Management
Pasadena,
California
|
+$29.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$11M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$8.25M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$46.2M |
| 2 |
DM
Deerfield Management
New York
|
-$34M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.5M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.5M |
| 5 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$9.35M |
NKTR Hedge Fund Activity: Q3 2013 in Review
142 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2013, worth a combined $1.29B — up 9.6% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NKTR positions and 17 closed out — a net gain of 5 holders — while 55 added to existing stakes and 42 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $287M. The largest seller was HealthCor Management, exiting entirely with an estimated $46.2M sold.
- 142 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2013, up from 139 in Q2 2013.
- Funds reported $1.29B of Nektar Therapeutics stock for Q3 2013, up 9.6% quarter-over-quarter.
- 22 funds opened new Nektar Therapeutics positions in Q3 2013 and 17 closed out, a net change of +5 holders.
- The largest Nektar Therapeutics buyer in Q3 2013 was OppenheimerFunds, an estimated $287M added.
- The largest Nektar Therapeutics seller in Q3 2013 was HealthCor Management, an estimated $46.2M sold.
Based on aggregated 13F filings for Q3 2013.